Abstract
Mutations of the N-ras oncogene and p53 tumor suppressor gene were simultaneously investigated in bone marrow cells from 44 patients with myelodysplastic syndrome (MDS) or MDS-derived leukemia by single-strand conformation polymorphism (SSCP) analysis followed by direct sequencing. The mutations of the N-ras gene were detected only in two cases with MDS-derived leukemia. Three patients with MDS-derived leukemia and one with refractory anemia with excess of blasts exhibited five mutations of the p53 gene. No concomitant mutations of both genes were observed in our study, suggesting that alterations of both genes could play an important role in the progression of MDS in a non-cooperative manner.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mitani, K., Hangaishi, A., Imamura, N. et al. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes. Leukemia 11, 863–865 (1997). https://doi.org/10.1038/sj.leu.2400666
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400666
Keywords
This article is cited by
-
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Journal of Hematology & Oncology (2012)
-
Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset
Leukemia (2006)
-
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
Leukemia (2004)
-
A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies
Leukemia (2000)